ALNY (STOCKS)
Alnylam Pharmaceuticals, Inc.
$227.500000
+3.550000 (+1.59%)
Prev close: $223.950000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Yvonne L. Greenstreet
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $30,890.04M
- Employees
- 2,230
- P/E (TTM)
- 37.81
- P/B (TTM)
- 22.12
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
21
Buy
8
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$1.21 | $1.59 | -0.3758 | -23.70% |
|
Mar 2026 (Q1)
|
$1.51 | $0.98 | +0.5285 | +53.85% |
|
Dec 2025 (Q4)
|
$0.82 | $1.15 | -0.3265 | -28.48% |
|
Sep 2025 (Q3)
|
$2.11 | $0.76 | +1.3487 | +177.16% |
Financial Statements
| Revenues | $4.80B |
| Benefits Costs and Expenses | $4.00B |
| Cost Of Revenue | $970.74M |
| Costs And Expenses | $3.80B |
| Gross Profit | $3.83B |
| Nonoperating Income/Loss | -$275.09M |
| Operating Expenses | $2.83B |
| Selling, General, and Administrative Expenses | $1.32B |
| Research and Development | $1.51B |
| Other Operating Expenses | $6.72M |
| Operating Income/Loss | $999.78M |
| Income/Loss From Continuing Operations After Tax | $698.43M |
| Income/Loss From Continuing Operations Before Tax | $724.69M |
| Income Tax Expense/Benefit | -$8.42M |
| Income Tax Expense/Benefit, Deferred | -$9.61M |
| Net Income/Loss | $733.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $733.11M |
| Net Income/Loss Available To Common Stockholders, Basic | $733.11M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $5.53 |
| Diluted Earnings Per Share | $5.37 |
| Basic Average Shares | 265,105,000 |
| Diluted Average Shares | 276,135,000 |
| Assets | $5.56B |
| Current Assets | $4.62B |
| Inventory | $97.11M |
| Other Current Assets | $4.52B |
| Noncurrent Assets | $938.60M |
| Fixed Assets | $554.14M |
| Other Non-current Assets | $384.45M |
| Liabilities | $4.20B |
| Current Liabilities | $1.51B |
| Accounts Payable | $108.02M |
| Other Current Liabilities | $1.40B |
| Noncurrent Liabilities | $2.69B |
| Equity | $1.35B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.35B |
| Liabilities And Equity | $5.56B |
| Net Cash Flow From Operating Activities | $911.81M |
| Net Cash Flow From Operating Activities, Continuing | $911.81M |
| Net Cash Flow From Investing Activities | $74.94M |
| Net Cash Flow From Investing Activities, Continuing | $74.94M |
| Net Cash Flow From Financing Activities | -$377.00M |
| Net Cash Flow From Financing Activities, Continuing | -$377.00M |
| Exchange Gains/Losses | -$16.14M |
| Net Cash Flow | $593.62M |
| Net Cash Flow, Continuing | $609.75M |
| Comprehensive Income/Loss | $735.72M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $735.72M |
| Other Comprehensive Income/Loss | $730.93M |
| Other Comprehensive Income/Loss Attributable To Parent | -$2.19M |